Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Red Biotechnology Market

ID: MRFR/HC/20255-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026

Red Biotechnology Market Research Report: Size, Share, Trend Analysis By Product (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal models, Molecular diagnostics and Others), By End-User (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Red Biotechnology Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Product (USD Billion)
  49.     4.1.1 Monoclonal Antibodies
  50.     4.1.2 Polyclonal Antibodies
  51.     4.1.3 Recombinant Proteins
  52.     4.1.4 Vaccines
  53.     4.1.5 Cell-Based Immunotherapy Products
  54.     4.1.6 Gene Therapy Products
  55.     4.1.7 Cell Therapy Products
  56.     4.1.8 Tissue-Engineered Products
  57.     4.1.9 Stem Cells
  58.     4.1.10 Cell Culture
  59.     4.1.11 Viral Vector
  60.     4.1.12 Enzymes
  61.     4.1.13 Kits and Reagents
  62.     4.1.14 Animal models
  63.     4.1.15 Molecular diagnostics
  64.     4.1.16 Others
  65.   4.2 Healthcare, BY End-User (USD Billion)
  66.     4.2.1 Academic Research Institutes
  67.     4.2.2 CMOs & CROs
  68.     4.2.3 Pharmaceutical & Biotechnology Companies
  69.     4.2.4 Others
  70.   4.3 Healthcare, BY Region (USD Billion)
  71.     4.3.1 North America
  72.       4.3.1.1 US
  73.       4.3.1.2 Canada
  74.     4.3.2 Europe
  75.       4.3.2.1 Germany
  76.       4.3.2.2 UK
  77.       4.3.2.3 France
  78.       4.3.2.4 Russia
  79.       4.3.2.5 Italy
  80.       4.3.2.6 Spain
  81.       4.3.2.7 Rest of Europe
  82.     4.3.3 APAC
  83.       4.3.3.1 China
  84.       4.3.3.2 India
  85.       4.3.3.3 Japan
  86.       4.3.3.4 South Korea
  87.       4.3.3.5 Malaysia
  88.       4.3.3.6 Thailand
  89.       4.3.3.7 Indonesia
  90.       4.3.3.8 Rest of APAC
  91.     4.3.4 South America
  92.       4.3.4.1 Brazil
  93.       4.3.4.2 Mexico
  94.       4.3.4.3 Argentina
  95.       4.3.4.4 Rest of South America
  96.     4.3.5 MEA
  97.       4.3.5.1 GCC Countries
  98.       4.3.5.2 South Africa
  99.       4.3.5.3 Rest of MEA
  100. 5 SECTION V: COMPETITIVE ANALYSIS
  101.   5.1 Competitive Landscape
  102.     5.1.1 Overview
  103.     5.1.2 Competitive Analysis
  104.     5.1.3 Market share Analysis
  105.     5.1.4 Major Growth Strategy in the Healthcare
  106.     5.1.5 Competitive Benchmarking
  107.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  108.     5.1.7 Key developments and growth strategies
  109.       5.1.7.1 New Product Launch/Service Deployment
  110.       5.1.7.2 Merger & Acquisitions
  111.       5.1.7.3 Joint Ventures
  112.     5.1.8 Major Players Financial Matrix
  113.       5.1.8.1 Sales and Operating Income
  114.       5.1.8.2 Major Players R&D Expenditure. 2023
  115.   5.2 Company Profiles
  116.     5.2.1 Amgen (US)
  117.       5.2.1.1 Financial Overview
  118.       5.2.1.2 Products Offered
  119.       5.2.1.3 Key Developments
  120.       5.2.1.4 SWOT Analysis
  121.       5.2.1.5 Key Strategies
  122.     5.2.2 Genentech (US)
  123.       5.2.2.1 Financial Overview
  124.       5.2.2.2 Products Offered
  125.       5.2.2.3 Key Developments
  126.       5.2.2.4 SWOT Analysis
  127.       5.2.2.5 Key Strategies
  128.     5.2.3 Gilead Sciences (US)
  129.       5.2.3.1 Financial Overview
  130.       5.2.3.2 Products Offered
  131.       5.2.3.3 Key Developments
  132.       5.2.3.4 SWOT Analysis
  133.       5.2.3.5 Key Strategies
  134.     5.2.4 Biogen (US)
  135.       5.2.4.1 Financial Overview
  136.       5.2.4.2 Products Offered
  137.       5.2.4.3 Key Developments
  138.       5.2.4.4 SWOT Analysis
  139.       5.2.4.5 Key Strategies
  140.     5.2.5 Regeneron Pharmaceuticals (US)
  141.       5.2.5.1 Financial Overview
  142.       5.2.5.2 Products Offered
  143.       5.2.5.3 Key Developments
  144.       5.2.5.4 SWOT Analysis
  145.       5.2.5.5 Key Strategies
  146.     5.2.6 Vertex Pharmaceuticals (US)
  147.       5.2.6.1 Financial Overview
  148.       5.2.6.2 Products Offered
  149.       5.2.6.3 Key Developments
  150.       5.2.6.4 SWOT Analysis
  151.       5.2.6.5 Key Strategies
  152.     5.2.7 Roche (CH)
  153.       5.2.7.1 Financial Overview
  154.       5.2.7.2 Products Offered
  155.       5.2.7.3 Key Developments
  156.       5.2.7.4 SWOT Analysis
  157.       5.2.7.5 Key Strategies
  158.     5.2.8 Sanofi (FR)
  159.       5.2.8.1 Financial Overview
  160.       5.2.8.2 Products Offered
  161.       5.2.8.3 Key Developments
  162.       5.2.8.4 SWOT Analysis
  163.       5.2.8.5 Key Strategies
  164.     5.2.9 AbbVie (US)
  165.       5.2.9.1 Financial Overview
  166.       5.2.9.2 Products Offered
  167.       5.2.9.3 Key Developments
  168.       5.2.9.4 SWOT Analysis
  169.       5.2.9.5 Key Strategies
  170.   5.3 Appendix
  171.     5.3.1 References
  172.     5.3.2 Related Reports
  173. 6 LIST OF FIGURES
  174.   6.1 MARKET SYNOPSIS
  175.   6.2 NORTH AMERICA MARKET ANALYSIS
  176.   6.3 US MARKET ANALYSIS BY PRODUCT
  177.   6.4 US MARKET ANALYSIS BY END-USER
  178.   6.5 CANADA MARKET ANALYSIS BY PRODUCT
  179.   6.6 CANADA MARKET ANALYSIS BY END-USER
  180.   6.7 EUROPE MARKET ANALYSIS
  181.   6.8 GERMANY MARKET ANALYSIS BY PRODUCT
  182.   6.9 GERMANY MARKET ANALYSIS BY END-USER
  183.   6.10 UK MARKET ANALYSIS BY PRODUCT
  184.   6.11 UK MARKET ANALYSIS BY END-USER
  185.   6.12 FRANCE MARKET ANALYSIS BY PRODUCT
  186.   6.13 FRANCE MARKET ANALYSIS BY END-USER
  187.   6.14 RUSSIA MARKET ANALYSIS BY PRODUCT
  188.   6.15 RUSSIA MARKET ANALYSIS BY END-USER
  189.   6.16 ITALY MARKET ANALYSIS BY PRODUCT
  190.   6.17 ITALY MARKET ANALYSIS BY END-USER
  191.   6.18 SPAIN MARKET ANALYSIS BY PRODUCT
  192.   6.19 SPAIN MARKET ANALYSIS BY END-USER
  193.   6.20 REST OF EUROPE MARKET ANALYSIS BY PRODUCT
  194.   6.21 REST OF EUROPE MARKET ANALYSIS BY END-USER
  195.   6.22 APAC MARKET ANALYSIS
  196.   6.23 CHINA MARKET ANALYSIS BY PRODUCT
  197.   6.24 CHINA MARKET ANALYSIS BY END-USER
  198.   6.25 INDIA MARKET ANALYSIS BY PRODUCT
  199.   6.26 INDIA MARKET ANALYSIS BY END-USER
  200.   6.27 JAPAN MARKET ANALYSIS BY PRODUCT
  201.   6.28 JAPAN MARKET ANALYSIS BY END-USER
  202.   6.29 SOUTH KOREA MARKET ANALYSIS BY PRODUCT
  203.   6.30 SOUTH KOREA MARKET ANALYSIS BY END-USER
  204.   6.31 MALAYSIA MARKET ANALYSIS BY PRODUCT
  205.   6.32 MALAYSIA MARKET ANALYSIS BY END-USER
  206.   6.33 THAILAND MARKET ANALYSIS BY PRODUCT
  207.   6.34 THAILAND MARKET ANALYSIS BY END-USER
  208.   6.35 INDONESIA MARKET ANALYSIS BY PRODUCT
  209.   6.36 INDONESIA MARKET ANALYSIS BY END-USER
  210.   6.37 REST OF APAC MARKET ANALYSIS BY PRODUCT
  211.   6.38 REST OF APAC MARKET ANALYSIS BY END-USER
  212.   6.39 SOUTH AMERICA MARKET ANALYSIS
  213.   6.40 BRAZIL MARKET ANALYSIS BY PRODUCT
  214.   6.41 BRAZIL MARKET ANALYSIS BY END-USER
  215.   6.42 MEXICO MARKET ANALYSIS BY PRODUCT
  216.   6.43 MEXICO MARKET ANALYSIS BY END-USER
  217.   6.44 ARGENTINA MARKET ANALYSIS BY PRODUCT
  218.   6.45 ARGENTINA MARKET ANALYSIS BY END-USER
  219.   6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT
  220.   6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
  221.   6.48 MEA MARKET ANALYSIS
  222.   6.49 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT
  223.   6.50 GCC COUNTRIES MARKET ANALYSIS BY END-USER
  224.   6.51 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT
  225.   6.52 SOUTH AFRICA MARKET ANALYSIS BY END-USER
  226.   6.53 REST OF MEA MARKET ANALYSIS BY PRODUCT
  227.   6.54 REST OF MEA MARKET ANALYSIS BY END-USER
  228.   6.55 KEY BUYING CRITERIA OF HEALTHCARE
  229.   6.56 RESEARCH PROCESS OF MRFR
  230.   6.57 DRO ANALYSIS OF HEALTHCARE
  231.   6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  232.   6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  233.   6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
  234.   6.61 HEALTHCARE, BY PRODUCT, 2024 (% SHARE)
  235.   6.62 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion)
  236.   6.63 HEALTHCARE, BY END-USER, 2024 (% SHARE)
  237.   6.64 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
  238.   6.65 BENCHMARKING OF MAJOR COMPETITORS
  239. 7 LIST OF TABLES
  240.   7.1 LIST OF ASSUMPTIONS
  241.     7.1.1
  242.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  243.     7.2.1 BY PRODUCT, 2025-2035 (USD Billion)
  244.     7.2.2 BY END-USER, 2025-2035 (USD Billion)
  245.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  246.     7.3.1 BY PRODUCT, 2025-2035 (USD Billion)
  247.     7.3.2 BY END-USER, 2025-2035 (USD Billion)
  248.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  249.     7.4.1 BY PRODUCT, 2025-2035 (USD Billion)
  250.     7.4.2 BY END-USER, 2025-2035 (USD Billion)
  251.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  252.     7.5.1 BY PRODUCT, 2025-2035 (USD Billion)
  253.     7.5.2 BY END-USER, 2025-2035 (USD Billion)
  254.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  255.     7.6.1 BY PRODUCT, 2025-2035 (USD Billion)
  256.     7.6.2 BY END-USER, 2025-2035 (USD Billion)
  257.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  258.     7.7.1 BY PRODUCT, 2025-2035 (USD Billion)
  259.     7.7.2 BY END-USER, 2025-2035 (USD Billion)
  260.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  261.     7.8.1 BY PRODUCT, 2025-2035 (USD Billion)
  262.     7.8.2 BY END-USER, 2025-2035 (USD Billion)
  263.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  264.     7.9.1 BY PRODUCT, 2025-2035 (USD Billion)
  265.     7.9.2 BY END-USER, 2025-2035 (USD Billion)
  266.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  267.     7.10.1 BY PRODUCT, 2025-2035 (USD Billion)
  268.     7.10.2 BY END-USER, 2025-2035 (USD Billion)
  269.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  270.     7.11.1 BY PRODUCT, 2025-2035 (USD Billion)
  271.     7.11.2 BY END-USER, 2025-2035 (USD Billion)
  272.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  273.     7.12.1 BY PRODUCT, 2025-2035 (USD Billion)
  274.     7.12.2 BY END-USER, 2025-2035 (USD Billion)
  275.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  276.     7.13.1 BY PRODUCT, 2025-2035 (USD Billion)
  277.     7.13.2 BY END-USER, 2025-2035 (USD Billion)
  278.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  279.     7.14.1 BY PRODUCT, 2025-2035 (USD Billion)
  280.     7.14.2 BY END-USER, 2025-2035 (USD Billion)
  281.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  282.     7.15.1 BY PRODUCT, 2025-2035 (USD Billion)
  283.     7.15.2 BY END-USER, 2025-2035 (USD Billion)
  284.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  285.     7.16.1 BY PRODUCT, 2025-2035 (USD Billion)
  286.     7.16.2 BY END-USER, 2025-2035 (USD Billion)
  287.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  288.     7.17.1 BY PRODUCT, 2025-2035 (USD Billion)
  289.     7.17.2 BY END-USER, 2025-2035 (USD Billion)
  290.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  291.     7.18.1 BY PRODUCT, 2025-2035 (USD Billion)
  292.     7.18.2 BY END-USER, 2025-2035 (USD Billion)
  293.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  294.     7.19.1 BY PRODUCT, 2025-2035 (USD Billion)
  295.     7.19.2 BY END-USER, 2025-2035 (USD Billion)
  296.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  297.     7.20.1 BY PRODUCT, 2025-2035 (USD Billion)
  298.     7.20.2 BY END-USER, 2025-2035 (USD Billion)
  299.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  300.     7.21.1 BY PRODUCT, 2025-2035 (USD Billion)
  301.     7.21.2 BY END-USER, 2025-2035 (USD Billion)
  302.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  303.     7.22.1 BY PRODUCT, 2025-2035 (USD Billion)
  304.     7.22.2 BY END-USER, 2025-2035 (USD Billion)
  305.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  306.     7.23.1 BY PRODUCT, 2025-2035 (USD Billion)
  307.     7.23.2 BY END-USER, 2025-2035 (USD Billion)
  308.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  309.     7.24.1 BY PRODUCT, 2025-2035 (USD Billion)
  310.     7.24.2 BY END-USER, 2025-2035 (USD Billion)
  311.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  312.     7.25.1 BY PRODUCT, 2025-2035 (USD Billion)
  313.     7.25.2 BY END-USER, 2025-2035 (USD Billion)
  314.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  315.     7.26.1 BY PRODUCT, 2025-2035 (USD Billion)
  316.     7.26.2 BY END-USER, 2025-2035 (USD Billion)
  317.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  318.     7.27.1 BY PRODUCT, 2025-2035 (USD Billion)
  319.     7.27.2 BY END-USER, 2025-2035 (USD Billion)
  320.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  321.     7.28.1 BY PRODUCT, 2025-2035 (USD Billion)
  322.     7.28.2 BY END-USER, 2025-2035 (USD Billion)
  323.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  324.     7.29.1 BY PRODUCT, 2025-2035 (USD Billion)
  325.     7.29.2 BY END-USER, 2025-2035 (USD Billion)
  326.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  327.     7.30.1 BY PRODUCT, 2025-2035 (USD Billion)
  328.     7.30.2 BY END-USER, 2025-2035 (USD Billion)
  329.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  330.     7.31.1
  331.   7.32 ACQUISITION/PARTNERSHIP
  332.     7.32.1

Healthcare Market Segmentation

Healthcare By Product (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell-Based Immunotherapy Products
  • Gene Therapy Products
  • Cell Therapy Products
  • Tissue-Engineered Products
  • Stem Cells
  • Cell Culture
  • Viral Vector
  • Enzymes
  • Kits and Reagents
  • Animal models
  • Molecular diagnostics
  • Others

Healthcare By End-User (USD Billion, 2025-2035)

  • Academic Research Institutes
  • CMOs & CROs
  • Pharmaceutical & Biotechnology Companies
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions